NASHVILLE, Tenn., Oct. 12,
2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX)
("Cryoport" or the "Company"), a leading global provider of
innovative products and services to the fast-growing cell and gene
therapy industry enabling the future of medicine for a new era of
life sciences, today announced that the Company has signed a new
three-year supply chain solutions agreement with Monash IVF Group
Limited (ASX: MVF), a leading provider of assisted
reproductive services, as well as specialist women's imaging and
diagnostic services in Australia
and Southeast Asia.
Founded in 1971, Monash IVF is a leader in the field of
fertility services and one of the largest providers of assisted
reproductive technologies (ART) and tertiary-level prenatal
diagnostics in Australia and
Southeast Asia. With more than 100
locations across Australia, Monash
IVF has achieved many Australian and world firsts in the industry.
Its operating businesses include Monash IVF, Repromed, Fertility
Solutions and KL Fertility Centre. Through this multi-year
agreement, Monash IVF and its operating businesses will utilize
Cryoport's cryogenic logistics solutions and ISO-certified risk
mitigation process for the delivery of patients' reproductive
materials throughout Australia and
internationally. Reproductive materials may be moved from one
clinic to another due to costs, a patients' personal move, access
to specific donor materials, for storage purposes and more.
"At Monash IVF, we pride ourselves on bringing together
specialists, sonographers, scientists, nurses and counselors who
are leaders in their respective fields to deliver the best patient
outcomes," said Michael Knaap, CEO
of Monash IVF. "It should come as no surprise that we are equally
dedicated to guaranteeing our partners' commitment to excellence.
Cryoport's expert team and world-class logistics capabilities will
provide our patients with the ease of knowing that their
reproductive materials are secure throughout the entire shipping
process."
"Monash IVF is Australia's
oldest IVF provider, having achieved the world's first IVF
pregnancy more than 50 years ago," added Jerrell Shelton, CEO of Cryoport. "To this day,
the company remains a prominent leader in the field of fertility
services. By joining forces and bringing our solutions and
expertise to Monash IVF, we have the opportunity to support many
more individuals and families throughout Australia and Southeast Asia in their plans to become
parents."
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is
a global provider of innovative products and services to the
fast-growing Cell & Gene Therapy industry - enabling the future
of medicine for a new era of life sciences. With 48 strategic
locations covering the Americas, EMEA (Europe, the Middle
East and Africa) and APAC
(Asia Pacific), Cryoport's global
platform provides mission-critical bio-logistics, bio-storage,
bio-processing, and cryogenic systems to the life sciences markets
worldwide.
For more information, visit www.cryoport.com or follow @cryoport
on Twitter at www.twitter.com/cryoport for live updates.
About Monash IVF Group
Monash IVF Group is a leading
provider of assisted reproductive services and specialist women's
imaging and diagnostic services in Australia and Malaysia. The Group is a driving force in the
development of assisted reproductive technologies and has many
Australian and world firsts since the work of our pioneers who
achieved the first IVF pregnancy in the world in 1973.
Forward-Looking Statements
Statements in
this press release which are not purely historical, including
statements regarding the Company's intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future, are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, those
related to the Company's industry, business, long-term growth
prospects, including expected growth in all of the Company's
markets, plans, strategies, acquisitions, future financial results
and financial condition, such as the Company's outlook and guidance
for full year 2023 revenue and the related assumptions and factors
expected to drive revenue, projected growth trends in the markets
in which the Company operates, the Company's plans and expectations
regarding the launch of new products and services, such as the
expected timing and benefits of such products and services
launches, the Company's plans to further strengthen its business
and continue to position itself for long-term and profitable growth
in the cell and gene therapy industry, and anticipated regulatory
filings or approvals with respect to the products of the Company's
clients. It is important to note that the Company's actual results
could differ materially from those in any such forward-looking
statements. Factors that could cause actual results to differ
materially include, but are not limited to, risks and uncertainties
associated with the effect of changing economic conditions,
including as a result of the COVID-19 pandemic and its variants,
supply chain constraints, inflationary pressures, the ongoing war
between Russia and Ukraine and the effects of foreign currency
fluctuations, trends in the products markets, variations in the
Company's cash flow, market acceptance risks, and technical
development risks. The Company's business could be affected by a
number of other factors discussed in the Company's SEC reports,
including in the "Risk Factors" section of its most recently filed
periodic reports on Form 10-K and Form 10-Q, as well as in its
subsequent filings with the SEC. The forward-looking statements
contained in this press release speak only as of the date hereof
and the Company cautions investors not to place undue reliance on
these forward-looking statements. Except as required by law, the
Company disclaims any obligation, and does not undertake to update
or revise any forward-looking statements in this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-inks-new-multi-year-supply-chain-solutions-agreement-with-monash-ivf-301954562.html
SOURCE Cryoport, Inc.